Education and Training
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-222, KITE-363, KITE-439, KITE-585, and KITE-718, in participants of Kite-sponsored interventional studies.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: Axicabtagene Ciloleucel
- biological: Brexucabtagene Autoleucel
- biological: KITE-585
- biological: KITE-718
- biological: KITE-439
- biological: KITE-222
- biological: KITE-363
Eligibility
Inclusion Criteria:
- The individual must have received an infusion of gene-modified cells in a completed
Kite-sponsored parent study, has not withdrawn full consent, and has discontinued or
completed the post-treatment follow-up period in the parent study, as applicable
- The individual must understand and voluntarily sign an Informed Consent Form (ICF) or
an Informed Assent Form prior to any study-related assessments or procedures being
conducted
- In the investigator's judgment, the individual is willing and able to complete the
protocol-required follow-up schedule and comply with the study requirements for
participation
Exclusion Criteria: none
Ages Eligible for Study
N/A - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kelly Chyan
650-625-8130
I'm interested